WASHINGTON D.C. (WDNews) – The U.S. Food and Drug Administration is launching a new program that could slash drug approval times for companies working on treatments tied to national health priorities.
Announced June 17, the Commissioner’s National Priority Voucher (CNPV) program will allow select drug developers to move through FDA review in as little as 1–2 months. Previously, it was 10–12 months.
“This national priority review program will bring more cures and meaningful treatments to the American public,” FDA Commissioner Dr. Marty Makary said. “We’re streamlining the process using a common-sense approach, modeled after multidisciplinary medical decision-making.”
Rather than the traditional back-and-forth between various FDA departments, the CNPV program will rely on pre-reviewed data and a one-day “tumor board-style” meeting with FDA scientists and physicians. The aim is to cut down inefficiencies and get important drugs to market faster without compromising safety or effectiveness.
In its first year, only a limited number of vouchers will be awarded/ Only companies aligned with specific national health goals such as fighting U.S. health crises, addressing unmet public health needs, developing innovative cures, or boosting domestic drug manufacturing.
“This approach capitalizes on frequent communication and allows for more efficient review without cutting corners,” Principal Deputy Commissioner Dr. Sara Brenner said.
The CNPV initiative reflects a broader FDA effort to modernize drug review and better support U.S. health and national security.
